ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.681,13
-0,46%
S&P 500
5.308,13
0,09%
Dow Jones
39.806,77
0,00%
Euro vs US Dollar
1,08655
0,05%
Bitcoin
71.276,15
-0,24%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Bright Minds Biosciences Inc (DRUG)

  7. Bright Minds Biosciences Inc (DRUG) News

DRUG

Bright Minds Biosciences (DRUG)

Bright Minds Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DRUG
DatumZeitQuelleÜberschriftSymbolFirma
27/02/202402h18Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:DRUGBright Minds Biosciences Inc
27/02/202402h10Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:DRUGBright Minds Biosciences Inc
13/02/202403h56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
18/01/202418h57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:DRUGBright Minds Biosciences Inc
29/12/202322h30Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:DRUGBright Minds Biosciences Inc
08/12/202312h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
06/12/202323h08PR Newswire (Canada)Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by ManagementNASDAQ:DRUGBright Minds Biosciences Inc
08/08/202322h24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
08/08/202312h50GlobeNewswire Inc.Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101NASDAQ:DRUGBright Minds Biosciences Inc
20/07/202319h49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
20/07/202312h50GlobeNewswire Inc.Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101NASDAQ:DRUGBright Minds Biosciences Inc
12/07/202322h55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
11/07/202312h50GlobeNewswire Inc.Bright Minds Announces Effective Date of Share ConsolidationNASDAQ:DRUGBright Minds Biosciences Inc
22/06/202321h37Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
22/06/202312h50GlobeNewswire Inc.Bright Minds Announces Proposed Share ConsolidationNASDAQ:DRUGBright Minds Biosciences Inc
15/05/202323h26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
19/04/202312h50GlobeNewswire Inc.Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202NASDAQ:DRUGBright Minds Biosciences Inc
10/04/202314h15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
10/04/202312h50GlobeNewswire Inc.Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin ResearchNASDAQ:DRUGBright Minds Biosciences Inc
02/03/202320h38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
27/02/202312h50GlobeNewswire Inc.Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023NASDAQ:DRUGBright Minds Biosciences Inc
17/02/202312h50GlobeNewswire Inc.Bright Minds Biosciences Announces Non-Executive Director AppointmentNASDAQ:DRUGBright Minds Biosciences Inc
08/02/202323h25Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
08/02/202322h05GlobeNewswire Inc.Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee RequirementsNASDAQ:DRUGBright Minds Biosciences Inc
07/02/202323h16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
27/01/202322h05GlobeNewswire Inc.Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:DRUGBright Minds Biosciences Inc
09/01/202322h05GlobeNewswire Inc.Bright Minds Biosciences Announces Resignation of Board MemberNASDAQ:DRUGBright Minds Biosciences Inc
06/12/202212h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
03/12/202201h06GlobeNewswire Inc.Bright Minds Biosciences Announces Closing of Non-Brokered Private PlacementNASDAQ:DRUGBright Minds Biosciences Inc
28/11/202212h50GlobeNewswire Inc.Bright Minds Biosciences Announces Non-Brokered Private PlacementNASDAQ:DRUGBright Minds Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:DRUG

Kürzlich von Ihnen besucht

NYSE
JWSM
Jaws Mustang Acquisition
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten